[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Lab Reports
June 2, 2010

Thalidomide for Vascular Disorder

JAMA. 2010;303(21):2129. doi:10.1001/jama.2010.688

Studies in mice and humans conducted by an international group of investigators indicate that thalidomide may be an effective treatment for hemorrhagic telangiectasia (HHT), an inherited disorder that is characterized by vascular malformations (Lebrin F et al. Nat Med. 2010;16[4]:420-428). Many with the disease develop recurrent nosebleeds that can severely affect their quality of life and are difficult to treat.

In a mouse model of HHT, thalidomide treatment rescued vessel wall defects, increased platelet-derived growth factor B expression in endothelial cells, and stimulated activation of cells involved in the formation of normal vasculature. The effects were partially reversed by pharmacological or genetic interference with platelet-derived growth factor signaling.

First Page Preview View Large
First page PDF preview
First page PDF preview